Advertisement

Indian Journal of Surgical Oncology

, Volume 10, Supplement 1, pp 65–70 | Cite as

Analysis of Clinical Outcomes of Pseudomyxoma Peritonei from Appendicular Origin Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy-A Retrospective Study from INDEPSO

  • Snita SinukumarEmail author
  • Sanket Mehta
  • Ramakrishnan AS
  • Dileep Damodaran
  • Mukurdipi Ray
  • Shabber Zaveri
  • Praveen Kammar
  • Aditi Bhatt
Original Article
  • 42 Downloads

Abstract

To evaluate the clinical outcomes of patients of pseudomyxoma peritonei of appendiceal origin undergoing cytoreductive surgery and HIPEC. Data collected from members, an independent collaborative group of Indian surgeons specializing in the management of peritoneal surface malignancy (INDEPSO), was analyzed retrospectively. Clinicopathological and perioperative outcomes of patients treated for pseudomyxoma peritonei (PMP) of appendicular origin were evaluated. Ninety-one patients were diagnosed with pseudomyxoma peritonei of appendicular origin between March 2013 and December 2017. The median age was 53 years and 60% were females. The median PCI was 27 [range 3–39] and a CC-0/1 resection was achieved in 83.5% patients. The most common histological grade was low-grade PMP, seen in 71.4% cases. The overall rate of grades 3–4 morbidity was 33% (30/91) and the 90-day mortality rate reported was 6.5%. Pulmonary complications and systemic sepsis emerged as the most significant factors affecting morbidity, mortality, and failure to rescue. At a median follow-up of 24 months, the median OS was not reached and the median PFS was 53 months. On univariate and multivariate analysis, high-grade histology, prior chemotherapy, debulking surgery alone without HIPEC, and high PCI > 10 were predictors of poor progression-free survival. The survival and morbidity results of pseudomyxoma peritonei from appendicular origin following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are encouraging. With further awareness and understanding of the disease, and improvement in surgical expertise and learning curve, there is scope for further reduction in morbidity and better improvement in survival.

Keywords

Pseudomyxoma peritonei Appendiceal tumor HIPEC 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Bevan KE, Mohamed F, Moran BJ (2010) Pseudomyxoma peritonei. World J Gastrointest Oncol 2(1):44–50CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Moran BJ, Cecil TD (2003) The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 12(3):585–603CrossRefPubMedGoogle Scholar
  3. 3.
    Esquivel J, Sugarbaker PH (2000) Clinical presentation of the Pseudomyxoma peritonei syndrome. Br J Surg 87(10):1414–1418CrossRefPubMedGoogle Scholar
  4. 4.
    Agrawal AK, Bobiński P, Grzebieniak Z, Rudnicki J, Marek G, Kobielak P et al (2014) Pseudomyxoma peritonei originating from urachus-case report and review of the literature. Curr Oncol Tor Ont 21(1):e155–e165CrossRefGoogle Scholar
  5. 5.
    Sugarbaker PH (1994) Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 219(2):109–111CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH (2003) Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 22(4):465–472CrossRefPubMedGoogle Scholar
  7. 7.
    Nitecki SS, Wolff BG, Schlinkert R, Sarr MG (1994) The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 219(1):51–57CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO et al (1994) Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 219(2):112–119CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG (2005) Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241(2):300–308CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Sugarbaker PH, Chang D (1999) Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 6(8):727–731CrossRefGoogle Scholar
  11. 11.
    Moran B, Baratti D, Yan TD, Kusamura S, Deraco M (2008) Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 98(4):277–282CrossRefPubMedGoogle Scholar
  12. 12.
    Mehta SS, Bhatt A, Glehen O (2016) Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol 7(2):139–151CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IHJT, Ceelen WP, Pelz JO, Piso P, González-Moreno S, van der Speeten K, Morris DL (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 30(20):2449–2456CrossRefGoogle Scholar
  14. 14.
    Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 42(7):1035–1041Google Scholar
  15. 15.
    Glehen O, Mohamed F, Sugarbaker PH (2004) Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 240(2):278–285CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Benhaim L, Honoré C, Goéré D, Delhorme J-B, Elias D (2016) Huge pseudomyxoma peritonei: surgical strategies and procedures to employ to optimize the rate of complete cytoreductive surgery. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 42(4):552–557Google Scholar
  17. 17.
    Sugarbaker PH (2013) Cytoreductive surgery and perioperative chemotherapy: textbook and video atlas. Cine-Med Publishing, WoodburyGoogle Scholar
  18. 18.
    Chua TC, Liauw W, Zhao J, Morris DL (2011) Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate. Ann Surg 253(4):769–773CrossRefPubMedGoogle Scholar
  19. 19.
    Austin F, Mavanur A, Sathaiah M, Steel J, Lenzner D, Ramalingam L et al (2012 May) Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol 19(5):1386–1393CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Newton AD, Bartlett EK, Karakousis GC (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol 7(1):99–111PubMedPubMedCentralGoogle Scholar
  21. 21.
    Kuijpers AMJ, Mirck B, Aalbers AGJ, Nienhuijs SW, de Hingh IHJT, Wiezer MJ, van Ramshorst B, van Ginkel RJ, Havenga K, Bremers AJ, de Wilt JHW, te Velde EA, Verwaal VJ (2013) Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 20(13):4224–4230CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B et al (2010) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 36(5):456–462Google Scholar
  23. 23.
    Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard A-C, Bakrin N, Cotte E, Gilly FN, Glehen O (2016) What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol 113(7):796–803CrossRefPubMedGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2019

Authors and Affiliations

  • Snita Sinukumar
    • 1
    Email author
  • Sanket Mehta
    • 2
  • Ramakrishnan AS
    • 3
  • Dileep Damodaran
    • 4
  • Mukurdipi Ray
    • 5
  • Shabber Zaveri
    • 6
  • Praveen Kammar
    • 2
  • Aditi Bhatt
    • 7
  1. 1.Department of Surgical OncologyJehangir hospitalPuneIndia
  2. 2.Department of Peritoneal Surface OncologySaifee HospitalMumbaiIndia
  3. 3.Department of Surgical OncologyCancer Institute (WIA)ChennaiIndia
  4. 4.Department of Surgical OncologyMVR Cancer Center and Research InstituteCalicutIndia
  5. 5.Department of Surgical OncologyAll India Institute of Medical SciencesNew DelhiIndia
  6. 6.Department of Surgical OncologyManipal HospitalBangaloreIndia
  7. 7.Department of Surgical OncologyZydus HospitalAhmedabadIndia

Personalised recommendations